Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

807
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
807
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

498
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
498
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

532
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview of methodology and characteristics of national acute coronary syndrome registries in high-income countries: a scoping review.

European heart journal open·2026
Same author

Associations between modifiable lifestyle risk factors and abdominal aortic calcification in the UK Biobank Imaging Study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

The relationship between time to urgent or emergency pacemaker implantation and entry into residential aged care or death in older adults.

Aging clinical and experimental research·2026
Same author

Obesity-Related Hypertension: An Emerging Clinical Phenotype.

The American journal of cardiology·2026
Same author

Automated Abdominal Aortic Calcification Scores and Atherosclerotic Cardiovascular Disease in the UK Biobank Imaging Study.

JACC. Advances·2026
Same author

Striving toward quality metrics for pediatric stroke: time from door to diagnosis.

Frontiers in stroke·2026

Related Experiment Video

Updated: Mar 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Device Therapies for Resistant Hypertension.

Dagmara Hering1, Carl Schultz2, Markus P Schlaich2

  • 1Dobney Hypertension Centre, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth.

Clinical Therapeutics
|September 28, 2016
PubMed
Summary

Resistant hypertension (RH) poses a significant public health challenge. Device-based therapies targeting sympathetic nervous system activation show promise for improving blood pressure control in RH patients.

Keywords:
baroreflexdenervationdevicesresistant hypertensionsympathetic

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

842
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

842
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Area of Science:

  • Cardiology
  • Nephrology
  • Medical Devices

Background:

  • Resistant hypertension (RH) affects approximately 10% of hypertensive patients despite multi-drug regimens.
  • Sustained high blood pressure (BP) increases the risk of target organ damage and cardiovascular mortality.
  • Optimized pharmacologic therapy, including mineralocorticoid receptor antagonists, may not adequately control BP in all RH patients.

Purpose of the Study:

  • To review device-based therapeutic approaches for resistant hypertension (RH).
  • To summarize clinical and experimental evidence for various device-based interventions.
  • To highlight the potential utility and limitations of these novel treatments.

Main Methods:

  • Review of existing clinical and experimental data on device-based therapies for RH.
  • Focus on approaches targeting pathophysiologic mechanisms of BP control, particularly sympathetic nervous system activation.
  • Inclusion of renal denervation, baroreflex activation therapy, central arteriovenous anastomosis, deep brain stimulation, and carotid body modulation.

Main Results:

  • Several device-based approaches demonstrate potential for improved BP control in RH.
  • These therapies generally exhibit an acceptable side effect profile.
  • Ongoing research is refining patient selection and procedural aspects.

Conclusions:

  • Device-based therapies represent a promising alternative strategy for managing uncontrolled resistant hypertension.
  • Further research is crucial to define the optimal role and implementation of these interventions.
  • Continued investigation will guide the future application of device-based approaches for RH.